These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10192613)

  • 21. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia.
    Bordbar M; Shakibazad N; Fattahi M; Haghpanah S; Honar N
    Turk J Gastroenterol; 2018 Mar; 29(2):203-209. PubMed ID: 29749328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.
    Parés A; Caballería L; Rodés J; Bruguera M; Rodrigo L; García-Plaza A; Berenguer J; Rodríguez-Martínez D; Mercader J; Velicia R
    J Hepatol; 2000 Apr; 32(4):561-6. PubMed ID: 10782903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial.
    Joutsiniemi T; Timonen S; Leino R; Palo P; Ekblad U
    Arch Gynecol Obstet; 2014 Mar; 289(3):541-7. PubMed ID: 23978872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
    Bacq Y; Sentilhes L; Reyes HB; Glantz A; Kondrackiene J; Binder T; Nicastri PL; Locatelli A; Floreani A; Hernandez I; Di Martino V
    Gastroenterology; 2012 Dec; 143(6):1492-501. PubMed ID: 22892336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of carriers of hepatitis B virus from a tertiary referral hospital: does the viral load change during the natural course of infection?
    Aakanksha ; Asim M; Sharma PK; Das BC; Kar P
    J Med Virol; 2011 Jul; 83(7):1151-8. PubMed ID: 21520137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged acute hepatitis A mimicking autoimmune hepatitis.
    Mikata R; Yokosuka O; Imazeki F; Fukai K; Kanda T; Saisho H
    World J Gastroenterol; 2005 Jun; 11(24):3791-3. PubMed ID: 15968741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B.
    Kadayifci A; Savas MC; Arslan S; Güllú IH
    J Clin Gastroenterol; 1997 Mar; 24(2):125-6. PubMed ID: 9077736
    [No Abstract]   [Full Text] [Related]  

  • 28. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial quantitative liver function tests in patients with primary biliary cirrhosis: a prospective long-term study.
    v Schönfeld J; Breuer N; Zotz RB; Beste M; Goebell H
    Digestion; 1997; 58(4):396-401. PubMed ID: 9324169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
    Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection.
    Fleckenstein JF; Paredes M; Thuluvath PJ
    Liver Transpl Surg; 1998 Jul; 4(4):276-9. PubMed ID: 9649640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.
    Poupon RE; Bonnand AM; Queneau PE; Trépo C; Zarski JPí ; Vetter D; Raabe JJ; Thieffin G; Larrey D; Grangé JD; Capron JP; Serfaty L; Chrétien Y; St Marc Girardin MF; Mathiex-Fortunet H; Zafrani ES; Guéchot J; Beuers U; Paumgartner G; Poupon R
    Scand J Gastroenterol; 2000 Jun; 35(6):642-9. PubMed ID: 10912666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
    Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
    Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
    Batts KP; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
    Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
    Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis.
    Lepage G; Paradis K; Lacaille F; Sénéchal L; Ronco N; Champagne J; Lenaerts C; Roy CC; Rasquin-Weber A
    J Pediatr; 1997 Jan; 130(1):52-8. PubMed ID: 9003851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corticotropin-releasing hormone expression in patients with intrahepatic cholestasis of pregnancy after ursodeoxycholic acid treatment: an initial experience.
    Zhou F; Zhang L; He MM; Liu ZF; Gao BX; Wang XD
    Curr Med Res Opin; 2014 Aug; 30(8):1529-35. PubMed ID: 24665980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
    J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
    Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
    Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.